期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

利奈唑胺在不同疾病患者中药动学变化的临床意义 被引量：6

Clinical significance of pharmacokinetics changes of linezolid in patients with different diseases
原文传递
导出
摘要 利奈唑胺是第一个用于临床的新型噁唑烷酮类抗菌药,在体内外对葡萄球菌、链球菌、肠球菌等多重耐药革兰阳性细菌有强大的抗菌作用,可作为治疗革兰阳性菌感染的糖肽类多重耐药的替换药物。现对其在囊性纤维化患者、肾功能不全患者、中性粒细胞减少的癌症患者、血液滤过患者等不同疾病患者中的药动学特点进行综述,以期为其在国内的临床合理应用提供参考。 Linezolid is the first oxazolidinone antibiotic and has been currently marketed in China. At present, linezolid can be used as an alternative drug to glycopeptides in treatment of multidrug-resistant Grampositive bacteria infections including methicillin-resistant Staphylococcus aureus （ MRSA）,Staphylococcus epidermidis, and vancomycin-resistant Enterococcus faecium and Enterococcus faecalis. In this paper, different pharmacokinetics profiles of linezolid in patients with cystic fibrosis, renal failure, neutropenia in cancer, and hemofiltration, etc, are reviewed to provide more information about rationally clinical application of linezolid in China.
作者 董海燕 董亚琳 杨华 刘娟娟
机构地区 西安交通大学医学院第一附属医院药学部
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2010年第3期170-174,共5页 Chinese Journal of New Drugs and Clinical Remedies
关键词 利奈唑胺 药动学 葡萄球菌 金黄色 耐甲氧西林 临床方案 linezolid pharmacokinetics methicillin-resistant Staphylococcus aureus clinical protocols
分类号 R978.1 [医药卫生—药品]
  • 相关文献

参考文献19

  • 1AMENT PW, JAMSHED N, HORNE JP. Linezolid: its role in the treatment of gram-positive, drug-resistant bacterial infections [J]. Am Fam Physician, 2002, 65(4): 663-670.
  • 2任少华,秦丽君,胡华成.恶唑烷酮类抗菌药利奈唑胺的研究进展[J].中国新药与临床杂志,2003,22(5):313-316. 被引量：11
  • 3KELLY S, COLLINS J, MAGUIRE M, et al. An outbreak of colonization with linezolid-resistant Staphylococcus epidermidis in an intensive therapy unit[J]. J Antimicrob Chemother, 2008, 61(14) : 901-907.
  • 4DIEKEMA DJ, JONES RN. Oxazolidinones[J]. Drugs, 2000, 59 (1): 7-16.
  • 5MEYER B, KORNEK GV, NIKFARDJAM M, et al. Multipledose pharmacokinetics of linezolid during continuous venovenous haemofiltration[J]. J Antimicrob Chemother, 2005, 56(1), 172- 179.
  • 6BEER R, ENGELHARDT KW, PFAUSLER B, et al. Pharmacokineties of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with Staphylococcal ventriculitis associated with external ventricular drains[J]. Antimicrob Agents Chemother, 2007, 51(1 ) : 379-382.
  • 7KOSAKA T, KOKUFU T, SHIME N, et al. Pharmacokinetics and tolerance of linezolid for meticillin-resistant Staphylococcus aureus mediastinitis in paediatric patients [J]. Int J Antimicrob Agents, 2009, 33(4): 368-370.
  • 8RAYNER CR, FORREST A, MEAGHER AK, et al. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme[J]. Clin Pharmacokinet, 2003, 42(15): 1411-1423.
  • 9SANTOS RP, PRESTIDGE CB, BROWN ME, et al. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis [J]. Pulmonology, 2009, 44(2) : 148-154.
  • 10SERISIER DJ, JONES G, CARROLL M. Eradication of pulmonary methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis with linezolid[J]. J Cyst Fibros, 2004, 3 (1): 61.

二级参考文献22

  • 1LINDEN P. Use of linezolid for gram-positive infections[J]. Infect Med, 2002,19 ( 1 ) : 25-32.
  • 2AMENT PW, JAMSHED N, HOME JP. Linezolid:its role in the treatment of gram-positive, drug-resistant bacterial infections [ J ].Am Fam Physician, 2002,65 (4) : 663-670.
  • 3DIEKEMA DJ, JONES RN. Oxazolidinone antibiotics[J]. Lancet,2001,358(9297) : 1975-1982.
  • 4LIVERMORE DM. Quinupristin/dalfopristin and linezolid: where,when, which and whether to use? [J]. J Antimicrob Chemother,2000,46 ( 3 ) : 347-350.
  • 5SISSON TL, JUNGNLUTH GL, HOPKINS NK. Age and sex effects on the pharmacokinetics of linezolid[J]. Eur J Clin Pharmacol,2002,57 ( 11 ) : 793-797.
  • 6GEE T, ELLIS R, MARSHALL G, et al. Pharmacokineties and tissue penetration of linezolid following multiple oral doses[J ]. Antimicrob Agents Chemother, 2001,45 (6) : 1843-1846.
  • 7FINES M, LECLERCQ R. Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors[J ].J Antimicrob Chemother,2000,45(4) :797-802.
  • 8FUNG FIB, KIRSCHENBAUM HL, OJOFEITIMI BO. Linezolid :an oxazolidinone antimicrobial agent [ J ]. Clin Ther, 2001,23(3) :356-391.
  • 9MUNCKHOF WJ, GILES C, TURNIDGE JD. Post-antibiotic growth suppression of linezolid against Gram-positive bacteria[J ]. J Antimicrob Chemother,2001,47(6) :879-883.
  • 10GANDER S, HAYWARD K, FINCH R. An investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing an in vitro pharmacokinetic model[J ]. J Antimicrob Chemother,2002,49(2) :301-308.

共引文献10

同被引文献43

  • 1MOELLERING RC. Linezolid: the first oxazolidinone antimi- crobial[J]. Ann Intern Med, 2003, 138(2) : 135-142.
  • 2MCGOWAN AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram positive infections[J]. J Antimicrob Chemother, 2003, 51 Suppl 2: ii17- ii25.
  • 3STALKER DJ, JUNGBLUTH GL, HOPKINS NK, et al. Pharmacokinetics and tolerance of single and multiple dose oral or intravenous linezolid, and oxazolidinone antibiotic, in healthy colunteers[J]. J Antimicrob Chemother, 2003, 51 (5): 1239- 1246.
  • 4PEA F, SCUDELLER L, LUGANO M, et O1. Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient[J]. Clin Infect Dis, 2006, 42(3): 433-434.
  • 5APODACA AA, RAKITA RM. Linezolid-indueed lactic acidosis [J]. N Engl J Med, 2003, 348 (1) : 86-87.
  • 6KOPTERIDES P, PAPADOMICHELAKIS E, ARMAGANIDIS A. Linezolid use associated with lactic acidosis[J]. Scand J Infect Dis, 2005, 37(2): 153-154.
  • 7PALENZUELA L, HAHN NM, NELSON RP Jr, et ol. Doeslinezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis?[J]. Clin Infect Dis, 2005, 40(12): el13-el16.
  • 8SWOBODA S, OBER MC, LICHTENSTERN C, et al. Pharmacokinetics of linezolid in septic patients with and without extended dialysis[J]. Eur J Clin Pharmacol, 2010, 66(3): 291- 298.
  • 9RADUNZ S, JUNTERMANNS B, KAISER GM, et ol. Efficacy and safety of linezolid in liver transplant patients [J]. Transpl Infect Dis, 2011, 13(4) : 353-358.
  • 10TAKAHASHI Y, TAKESUE Y, NAKAJIMA K, eta!. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy[J]. J Infect Chemother, 2011, 17(3): 382-387.

引证文献6

二级引证文献42

中国新药与临床杂志
2010年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部